Nurix Therapeutics第四季度每股收益$(0.75)不及预期$(0.68),销售额$1328万超过预期$1286万

财报速递2025-01-29
Nurix Therapeutics(NRIX) (NASDAQ:NRIX)报告季度每股亏损$(0.75),未达到分析师普遍预期的$(0.68),相差10.29%。这比去年同期每股亏损$(0.77)增加了2.6%。公司报告季度销售额为1328万美元,超过分析师普遍预期的1286万美元,超出3.31%。这比去年同期的销售额1516万美元减少了12.37%。

以上内容来自Benzinga Earnings专栏,原文如下:

Nurix Therapeutics (NASDAQ:NRIX) reported quarterly losses of $(0.75) per share which missed the analyst consensus estimate of $(0.68) by 10.29 percent. This is a 2.6 percent increase over losses of $(0.77) per share from the same period last year. The company reported quarterly sales of $13.28 million which beat the analyst consensus estimate of $12.86 million by 3.31 percent. This is a 12.37 percent decrease over sales of $15.16 million the same period last year.

免责声明:本文观点仅代表作者个人观点,不构成本平台的投资建议,本平台不对文章信息准确性、完整性和及时性做出任何保证,亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白
发表看法